\-\ Texto\\:\\ \ \(0\)\
\-\ nontender\\,\\ right\\ testicular\\ mass\\ on\\ examination\\.\ \(0\)\
\-\ ldh\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\ \\ 287\\ \\(115\\-222\\)\\ \\ \\ \\ \\ \\ \\ units\\/l\ \(0\)\
\-\ b\\-hcg\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\.\\ \\ \\<2\\ \\(9\\)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ miu\\/ml\ \(0\)\
\-\ afp\\ tumor\\ mark\\.\\ \\.\\ \\.\\ \\.\\ \\.\\ 2\\.0\\ \\(0\\.0\\-6\\.1\\)\\ \\ \\ \\ \\ \\ \\ ng\\/ml\ \(0\)\
\-\ imaging\\ for\\ metastatic\\ disease\\ surveillance\\.\ \(0\)\
\-\ the\\ right\\ testicle\\ is\\ enlarged\\.\\ there\\ is\\ a\\ hypoechoic\\,\\ heterogeneous\\ expansile\\ mass\ \(0\)\
\-\ within\\ the\\ right\\ testicle\\ which\\ has\\ nearly\\ replaced\\ the\\ normal\\ testicular\\ tissue\\.\\ this\\ mass\\ is\\ hypervascular\\ in\\ appearance\\.\\ the\\ right\\ epididymis\\ is\\ normal\\ in\\ size\\ and\\ appearance\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ imaging\\ of\\ the\\ right\\ renal\\ fossa\\ shows\\ no\\ ultrasonographic\\ evidence\\ of\\ lymphadenopathy\\.\ \(0\)\
\-\ seminoma\ \(37\)\
\-\ tumor\\:\ \(13\)\
\-\ \\ \\ \\-primary\\:\\ germinal\\(95\\%\\)\\,\\ nongerminal\ \(0\)\
\-\ \\ \\ \\-metastases\\ \\/\\ lymphoma\\ in\\ pt\\ over\\ 50\\:\\ prostate\\,\\ kidney\\,\\ leukemia\\,\\ lymphoma\ \(0\)\
\-\ infection\\:\ \(1\)\
\-\ \\ \\ \\-orchitis\ \(0\)\
\-\ \\ \\ \\-abscess\ \(0\)\
\-\ \\ \\ \\-granulomas\\ \\(tb\\,\\ sarcoid\\,\\ histo\\ \\-\\ often\\ bilateral\\/multiple\\)\ \(0\)\
\-\ trauma\\:\ \(4\)\
\-\ \\ \\ \\-fracture\\,\\ rupture\\,\\ hemorrhage\\,\\ torsion\\ \\(not\\ with\\ internal\\ blood\\ flow\\)\ \(1\)\
\-\ presented\\ to\\ the\\ er\\ with\\ right\\ testicular\\ mass\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ testicular\\:\\ 0\\.30513418571663525\ \(0\)\
\-\ testicle\\:\\ 0\\.21819045585007174\ \(0\)\
\-\ right\\:\\ 0\\.21574047104081176\ \(0\)\
\-\ nongerminal\\:\\ 0\\.17344038340147588\ \(0\)\
\-\ mass\\:\\ 0\\.16570501040005217\ \(0\)\
\-\ 287\\:\\ 0\\.16026203822532178\ \(0\)\
\-\ histo\\:\\ 0\\.14708369304916769\ \(0\)\
\-\ mark\\:\\ 0\\.1448443627261024\ \(0\)\
\-\ ultrasonographic\\:\\ 0\\.14102914459392618\ \(0\)\
\-\ germinal\\:\\ 0\\.13644409120662557\ \(0\)\
\-\ epididymis\\:\\ 0\\.13275273236092944\ \(0\)\
\-\ appearance\\:\\ 0\\.13076454181971464\ \(0\)\
\-\ the\\:\\ 0\\.12984213855241508\ \(0\)\
\-\ lymphoma\\:\\ 0\\.12918127121229012\ \(0\)\
\-\ replaced\\:\\ 0\\.12259857816464222\ \(0\)\
\-\ seminoma\\:\\ 0\\.1190232664741441\ \(0\)\
\-\ is\\:\\ 0\\.11880265540047188\ \(0\)\
\-\ surveillance\\:\\ 0\\.11848767237379418\ \(0\)\
\-\ ldh\\:\\ 0\\.11796675394629394\ \(0\)\
\-\ hypervascular\\:\\ 0\\.11467245424161795\ \(0\)\
\-\ afp\\:\\ 0\\.11424519281746681\ \(0\)\
\-\ imaging\\:\\ 0\\.11399172365728309\ \(0\)\
\-\ tumor\\:\\ 0\\.113454701516691\ \(0\)\
\-\ nearly\\:\\ 0\\.10815227435276853\ \(0\)\
\-\ torsion\\:\\ 0\\.10815227435276853\ \(0\)\
\-\ prostate\\:\\ 0\\.10504708396087327\ \(0\)\
\-\ 95\\:\\ 0\\.10283671378542238\ \(0\)\
\-\ nontender\\:\\ 0\\.10215356245229384\ \(0\)\
\-\ sarcoid\\:\\ 0\\.10171139523887841\ \(0\)\
\-\ leukemia\\:\\ 0\\.09906369840805063\ \(0\)\
\-\ expansile\\:\\ 0\\.09813608354838028\ \(0\)\
\-\ tb\\:\\ 0\\.09657254542027048\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.09266657612183588\ \(0\)\
\-\ normal\\:\\ 0\\.08856148296678365\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.08767841929741181\ \(0\)\
\-\ rupture\\:\\ 0\\.08767841929741181\ \(0\)\
\-\ fossa\\:\\ 0\\.0851396759637998\ \(0\)\
\-\ er\\:\\ 0\\.08111784491765993\ \(0\)\
\-\ in\\:\\ 0\\.08093895881550305\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.07849605801640029\ \(0\)\
\-\ pt\\:\\ 0\\.07805018722194018\ \(0\)\
\-\ kidney\\:\\ 0\\.07619238809476632\ \(0\)\
\-\ 50\\:\\ 0\\.07574103554521879\ \(0\)\
\-\ enlarged\\:\\ 0\\.07393403592595947\ \(0\)\
\-\ size\\:\\ 0\\.07343368249044026\ \(0\)\
\-\ internal\\:\\ 0\\.07309110865946701\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.0726121832545223\ \(0\)\
\-\ flow\\:\\ 0\\.0722375438767868\ \(0\)\
\-\ often\\:\\ 0\\.07076574953245593\ \(0\)\
\-\ examination\\:\\ 0\\.06939974981377085\ \(0\)\
\-\ renal\\:\\ 0\\.0675369136397447\ \(0\)\
\-\ infection\\:\\ 0\\.06551204843241094\ \(0\)\
\-\ shows\\:\\ 0\\.06365268514783326\ \(0\)\
\-\ presented\\:\\ 0\\.06324380200760017\ \(0\)\
\-\ trauma\\:\\ 0\\.06298551728200402\ \(0\)\
\-\ blood\\:\\ 0\\.06298551728200402\ \(0\)\
\-\ evidence\\:\\ 0\\.06155823648573885\ \(0\)\
\-\ over\\:\\ 0\\.06030478424263331\ \(0\)\
\-\ metastatic\\:\\ 0\\.05948119136121047\ \(0\)\
\-\ tissue\\:\\ 0\\.056892139076933246\ \(0\)\
\-\ within\\:\\ 0\\.04995023021672992\ \(0\)\
\-\ has\\:\\ 0\\.049538292052108836\ \(0\)\
\-\ which\\:\\ 0\\.04931477931495785\ \(0\)\
\-\ disease\\:\\ 0\\.04552482842450013\ \(0\)\
\-\ there\\:\\ 0\\.0431532181397021\ \(0\)\
\-\ not\\:\\ 0\\.042814769762551094\ \(0\)\
\-\ with\\:\\ 0\\.04247301087508941\ \(0\)\
\-\ of\\:\\ 0\\.042447648415276\ \(0\)\
\-\ this\\:\\ 0\\.03726649543625893\ \(0\)\
\-\ no\\:\\ 0\\.03526776819004615\ \(0\)\
\-\ for\\:\\ 0\\.03287135271747594\ \(0\)\
\-\ on\\:\\ 0\\.03275474803898178\ \(0\)\
\-\ to\\:\\ 0\\.02711310357815955\ \(0\)\
\-\ and\\:\\ 0\\.02241053972381684\ \(0\)\
